Evaluation of clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis.

3 A), the pooled analysis for the ECOG = 0 subgroup demonstrated a marginally significant improvement in OS for the vaccines group (HR = 0.73, 95% CI, 0.53–1.00, P = 0.05), and the ECOG = 1 subgroup demonstrated significantly better OS in the vaccines group (HR = 0.80, 95% CI, 0.68–0.95, P = 0.009).

also in 26,082 other papers